KYTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kyverna Therapeutics Inc (KYTX) is not a strong buy for a beginner, long-term investor at this time. The lack of strong technical signals, neutral trading sentiment, and underwhelming financial performance do not support immediate investment. While the company has a promising cash runway and leadership in its niche, the stock's technical indicators and options data suggest a cautious approach.
The MACD histogram is negative (-0.104) and contracting, RSI is neutral at 43.304, and moving averages are converging. Support is at 7.688, and resistance is at 9.078. The stock is trading below the pivot level of 8.383, indicating a lack of upward momentum.
Kyverna has a strong cash runway extending into 2028, leadership in the CAR-T autoimmune treatment space, and upcoming product launches and clinical trials. The company also beat EPS expectations in Q4 2025.
The company reported a net loss of $37.8 million in Q4 2025, with EPS dropping 8.05% YoY. Technical indicators do not show strong upward momentum, and there is no significant insider or hedge fund activity.
In Q4 2025, revenue remained at $0 with no growth. Net income improved slightly by 0.84% YoY but remains negative at -$37.8 million. EPS decreased by 8.05% YoY to -$0.80.
No analyst rating or price target changes were provided for this stock.
